{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T23:50:19Z","timestamp":1725666619482},"publisher-location":"New York, NY","reference-count":84,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781461408864"},{"type":"electronic","value":"9781461408871"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012]]},"DOI":"10.1007\/978-1-4614-0887-1_10","type":"book-chapter","created":{"date-parts":[[2012,3,6]],"date-time":"2012-03-06T09:37:07Z","timestamp":1331026627000},"page":"158-170","source":"Crossref","is-referenced-by-count":9,"title":["FGF23 as a Novel Therapeutic Target"],"prefix":"10.1007","author":[{"given":"Takashi","family":"Shimada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10_CR1","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1006\/bbrc.2000.3696","volume":"277","author":"T Yamashita","year":"2000","unstructured":"Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000; 277:494\u2013498.","journal-title":"Biochem Biophys Res Commun"},{"key":"10_CR2","doi-asserted-by":"crossref","unstructured":"The ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26:345\u2013348.","DOI":"10.1038\/81664"},{"key":"10_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1210\/jc.86.2.497","volume":"86","author":"KE White","year":"2001","unstructured":"White KE, Jonsson KB, Carn G et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 2001; 86:497\u2013500.","journal-title":"J Clin Endocrinol Metab"},{"key":"10_CR4","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1073\/pnas.101545198","volume":"98","author":"T Shimada","year":"2001","unstructured":"Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98:6500\u20136505.","journal-title":"Proc Natl Acad Sci USA"},{"key":"10_CR5","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1210\/en.143.8.3179","volume":"143","author":"T Shimada","year":"2002","unstructured":"Shimada T, Muto T, Urakawa I et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002; 143:3179\u20133182.","journal-title":"Endocrinology"},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"9843","DOI":"10.1074\/jbc.M210490200","volume":"278","author":"XY Bai","year":"2003","unstructured":"Bai XY, Miao D, Goltzman D et al. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 2003; 278:9843\u20139849.","journal-title":"J Biol Chem"},{"key":"10_CR7","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1210\/en.2004-0233","volume":"145","author":"X Bai","year":"2004","unstructured":"Bai X, Miao D, Li J et al. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004; 145:5269\u20135279.","journal-title":"Endocrinology"},{"key":"10_CR8","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1210\/en.2003-1768","volume":"145","author":"T Larsson","year":"2004","unstructured":"Larsson T, Marsell R, Schipani E et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia and disturbed phosphate homeostasis. Endocrinology 2004; 145:3087\u20133094.","journal-title":"Endocrinology"},{"key":"10_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.bbrc.2003.12.102","volume":"314","author":"T Shimada","year":"2004","unstructured":"Shimada T, Urakawa I, Yamazaki Y et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004; 314:409\u2013414.","journal-title":"Biochem Biophys Res Commun"},{"key":"10_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00774-004-0589-9","volume":"23","author":"T Yamamoto","year":"2005","unstructured":"Yamamoto T, Imanishi Y, Kinoshita E et al. The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome. J Bone Miner Metab 2005; 23:231\u2013237.","journal-title":"J Bone Miner Metab"},{"key":"10_CR11","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1359\/jbmr.2003.18.7.1227","volume":"18","author":"TJ Weber","year":"2003","unstructured":"Weber TJ, Liu S, Indridason OS et al. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003; 18:1227\u20131234.","journal-title":"J Bone Miner Res"},{"key":"10_CR12","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI18399","volume":"112","author":"M Riminucci","year":"2003","unstructured":"Riminucci M, Collins MT, Fedarko NS et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003; 112:683\u2013692.","journal-title":"J Clin Invest"},{"key":"10_CR13","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa020881","volume":"348","author":"KB Jonsson","year":"2003","unstructured":"Jonsson KB, Zahradnik R, Larsson T et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348:1656\u20131663.","journal-title":"N Engl J Med"},{"key":"10_CR14","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1210\/jc.2002-021105","volume":"87","author":"Y Yamazaki","year":"2002","unstructured":"Yamazaki Y, Okazaki R, Shibata M et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia. J Clin Endocrinol Metab 2002; 87:4957\u20134960.","journal-title":"J Clin Endocrinol Metab"},{"key":"10_CR15","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.bone.2008.02.014","volume":"42","author":"I Endo","year":"2008","unstructured":"Endo I, Fukumoto S, Ozono K et al. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone 2008; 42:1235\u20131239.","journal-title":"Bone"},{"key":"10_CR16","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1359\/jbmr.060507","volume":"21","author":"SM Burnett","year":"2006","unstructured":"Burnett SM, Gunawardene SC, Bringhurst FR et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006; 21:1187\u20131196.","journal-title":"J Bone Miner Res"},{"key":"10_CR17","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1210\/jc.2004-1039","volume":"90","author":"SL Ferrari","year":"2005","unstructured":"Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90:1519\u20131524.","journal-title":"J Clin Endocrinol Metab"},{"key":"10_CR18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1172\/JCI200419081","volume":"113","author":"T Shimada","year":"2004","unstructured":"Shimada T, Kakitani M, Yamazaki Y et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113:561\u2013568.","journal-title":"J Clin Invest"},{"key":"10_CR19","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.matbio.2004.09.007","volume":"23","author":"D Sitara","year":"2004","unstructured":"Sitara D, Razzaque MS, Hesse M et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004; 23:421\u2013432.","journal-title":"Matrix Biol"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1210\/jcem-60-6-1093","volume":"60","author":"KW Lyles","year":"1985","unstructured":"Lyles KW, Burkes EJ, Ellis GJ et al. Genetic transmission of tumoral calcinosis: autosomal dominant with variable clinical expressivity. J Clin Endocrinol Metab 1985; 60:1093\u20131096.","journal-title":"J Clin Endocrinol Metab"},{"key":"10_CR21","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1097\/00000478-199308000-00004","volume":"17","author":"RE Slavin","year":"1993","unstructured":"Slavin RE, Wen J, Kumar D et al. Familial tumoral calcinosis. A clinical, histopathologic and ultrastructural study with an analysis of its calcifying process and pathogenesis. Am J Surg Pathol 1993; 17:788\u2013802.","journal-title":"Am J Surg Pathol"},{"key":"10_CR22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/ng1358","volume":"36","author":"O Topaz","year":"2004","unstructured":"Topaz O, Shurman DL, Bergman R et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 2004; 36:579\u2013581.","journal-title":"Nat Genet"},{"key":"10_CR23","doi-asserted-by":"publisher","first-page":"5523","DOI":"10.1210\/jc.2005-0301","volume":"90","author":"K Araya","year":"2005","unstructured":"Araya K, Fukumoto S, Backenroth R et al. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 2005; 90:5523\u20135527.","journal-title":"J Clin Endocrinol Metab"},{"key":"10_CR24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/hmg\/ddi034","volume":"14","author":"A Benet-Pages","year":"2005","unstructured":"Benet-Pages A, Orlik P, Strom TM et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005; 14:385\u2013390.","journal-title":"Hum Mol Genet"},{"key":"10_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00439-005-0026-8","volume":"118","author":"I Chefetz","year":"2005","unstructured":"Chefetz I, Heller R, Galli-Tsinopoulou A et al. A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification. Hum Genet 2005; 118:261\u2013266.","journal-title":"Hum Genet"},{"key":"10_CR26","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1210\/en.2005-0431","volume":"146","author":"T Larsson","year":"2005","unstructured":"Larsson T, Davis SI, Garringer HJ et al. Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 2005; 146:3883\u20133891.","journal-title":"Endocrinology"},{"key":"10_CR27","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1210\/jc.2004-2238","volume":"90","author":"T Larsson","year":"2005","unstructured":"Larsson T, Yu X, Davis SI et al. A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 2005; 90:2424\u20132427.","journal-title":"J Clin Endocrinol Metab"},{"key":"10_CR28","first-page":"4003","volume":"117","author":"IZ Ben-Dov","year":"2007","unstructured":"Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117:4003\u20134008.","journal-title":"J Clin Invest"},{"key":"10_CR29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1677\/JOE-07-0267","volume":"195","author":"T Krajisnik","year":"2007","unstructured":"Krajisnik T, Bjorklund P, Marsell R et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007; 195:125\u2013131.","journal-title":"J Endocrinol"},{"key":"10_CR30","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1074\/jbc.M207872200","volume":"278","author":"H Saito","year":"2003","unstructured":"Saito H, Kusano K, Kinosaki M et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate cotransport activity and 1alpha, 25-dihydroxyvitamin D3 production. J Biol Chem 2003; 278:2206\u20132211.","journal-title":"J Biol Chem"},{"key":"10_CR31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19:429\u2013435.","journal-title":"J Bone Miner Res"},{"key":"10_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/9780470623992.ch28","volume-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","author":"D Bikle","year":"2008","unstructured":"Bikle D, Adams J, Christakos S. Vitamin D: Production, metabolism, mechanism of action and clinical requirements. In: Seeman E, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th ed. Washington D.C.: The American Society for Bone and Research, 2008; 141\u2013149.","edition":"7th ed"},{"key":"10_CR33","first-page":"76","volume-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","author":"M Favus","year":"2006","unstructured":"Favus M, Bushinsky DA, Lemann J. Regulation of calcium, magnesium and phosphate metabolism. In: Christakos S, Holick MF, eds. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, sixth ed. Washington, D.C.: the American Society for Bone and Mineral Research, 2006; 76\u201383."},{"key":"10_CR34","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1159\/000107069","volume":"27","author":"K Miyamoto","year":"2007","unstructured":"Miyamoto K, Ito M, Tatsumi S et al. New aspect of renal phosphate reabsorption: the type IIc sodium-dependent phosphate transporter. Am J Nephrol 2007; 27:503\u2013515.","journal-title":"Am J Nephrol"},{"key":"10_CR35","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jsbmb.2006.12.090","volume":"103","author":"HS Tenenhouse","year":"2007","unstructured":"Tenenhouse HS. Phosphate transport: molecular basis, regulation and pathophysiology. J Steroid Biochem Mol Biol 2007; 103:572\u2013577.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10_CR36","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.1073\/pnas.95.9.5372","volume":"95","author":"L Beck","year":"1998","unstructured":"Beck L, Karaplis AC, Amizuka N et al. Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria and skeletal abnormalities. Proc Natl Acad Sci USA 1998; 95:5372\u20135377.","journal-title":"Proc Natl Acad Sci USA"},{"key":"10_CR37","doi-asserted-by":"publisher","first-page":"F671","DOI":"10.1152\/ajprenal.00156.2009","volume":"297","author":"H Segawa","year":"2009","unstructured":"Segawa H, Onitsuka A, Furutani J et al. Npt2a and Npt2c in mice play distinct and synergistic roles in inorganic phosphate metabolism and skeletal development. Am J Physiol Renal Physiol 2009; 297:F671\u2013678.","journal-title":"Am J Physiol Renal Physiol"},{"key":"10_CR38","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1086\/499409","volume":"78","author":"C Bergwitz","year":"2006","unstructured":"Bergwitz C, Roslin NM, Tieder M et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet 2006; 78:179\u2013192.","journal-title":"Am J Hum Genet"},{"key":"10_CR39","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1210\/jc.2005-2840","volume":"91","author":"S Ichikawa","year":"2006","unstructured":"Ichikawa S, Sorenson AH, Imel EA et al. Intronic deletions in the SLC34A3 gene cause hereditary hypophosphatemic rickets with hypercalciuria. J Clin Endocrinol Metab 2006; 91:4022\u20134027.","journal-title":"J Clin Endocrinol Metab"},{"key":"10_CR40","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1086\/499410","volume":"78","author":"B Lorenz-Depiereux","year":"2006","unstructured":"Lorenz-Depiereux B, Benet-Pages A, Eckstein G et al. Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet 2006; 78:193\u2013201.","journal-title":"Am J Hum Genet"},{"key":"10_CR41","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00774-007-0776-6","volume":"25","author":"T Yamamoto","year":"2007","unstructured":"Yamamoto T, Michigami T, Aranami F et al. Hereditary hypophosphatemic rickets with hypercalciuria: a study for the phosphate transporter gene type IIc and osteoblastic function. J Bone Miner Metab 2007; 25:407\u2013413.","journal-title":"J Bone Miner Metab"},{"key":"10_CR42","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11154-008-9075-3","volume":"9","author":"M Bastepe","year":"2008","unstructured":"Bastepe M, Juppner H. Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation. Rev Endocr Metab Disord 2008; 9:171\u2013180.","journal-title":"Rev Endocr Metab Disord"},{"key":"10_CR43","doi-asserted-by":"publisher","first-page":"F371","DOI":"10.1152\/ajprenal.00090.2008","volume":"295","author":"G Jaureguiberry","year":"2008","unstructured":"Jaureguiberry G, Carpenter TO, Forman S et al. A novel missense mutation in SLC34A3 that causes hereditary hypophosphatemic rickets with hypercalciuria in humans identifies threonine 137 as an important determinant of sodium-phosphate cotransport in NaPi-IIc. Am J Physiol Renal Physiol 2008; 295:F371\u2013379.","journal-title":"Am J Physiol Renal Physiol"},{"key":"10_CR44","doi-asserted-by":"publisher","first-page":"F369","DOI":"10.1152\/ajprenal.90327.2008","volume":"295","author":"M Levi","year":"2008","unstructured":"Levi M. Novel NaPi-2c mutations that cause mistargeting of NaPi-2c protein and uncoupling of Na-Pi cotransport cause HHRH. Am J Physiol Renal Physiol 2008; 295:F369\u2013370.","journal-title":"Am J Physiol Renal Physiol"},{"key":"10_CR45","doi-asserted-by":"publisher","first-page":"28265","DOI":"10.1074\/jbc.M202527200","volume":"277","author":"T Yamashita","year":"2002","unstructured":"Yamashita T, Konishi M, Miyake A et al. Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 2002; 277:28265\u201328270.","journal-title":"J Biol Chem"},{"key":"10_CR46","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00424-003-1084-1","volume":"446","author":"H Segawa","year":"2003","unstructured":"Segawa H, Kawakami E, Kaneko I et al. Effect of hydrolysis-resistant FGF23-R179Q on dietary phosphate regulation of the renal type-II Na\/Pi transporter. Pflugers Arch 2003; 446:585\u2013592.","journal-title":"Pflugers Arch"},{"key":"10_CR47","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/j.1523-1755.2005.00506.x","volume":"68","author":"M Baum","year":"2005","unstructured":"Baum M, Schiavi S, Dwarakanath V et al. Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int 2005; 68:1148\u20131153.","journal-title":"Kidney Int"},{"key":"10_CR48","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1073\/pnas.95.4.1909","volume":"95","author":"MF Pfister","year":"1998","unstructured":"Pfister MF, Ruf I, Stange G et al. Parathyroid hormone leads to the lysosomal degradation of the renal type II Na\/Pi cotransporter. Proc Natl Acad Sci USA 1998; 95:1909\u20131914.","journal-title":"Proc Natl Acad Sci USA"},{"key":"10_CR49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bbaexp.2005.11.003","volume":"1732","author":"H Yamamoto","year":"2005","unstructured":"Yamamoto H, Tani Y, Kobayashi K et al. Alternative promoters and renal cell-specific regulation of the mouse type IIa sodium-dependent phosphate cotransporter gene. Biochim Biophys Acta 2005; 1732:43\u201352.","journal-title":"Biochim Biophys Acta"},{"key":"10_CR50","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1042\/BJ20041799","volume":"390","author":"Y Inoue","year":"2005","unstructured":"Inoue Y, Segawa H, Kaneko I et al. Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem J 2005; 390:325\u2013331.","journal-title":"Biochem J"},{"key":"10_CR51","doi-asserted-by":"publisher","first-page":"F1088","DOI":"10.1152\/ajprenal.00474.2004","volume":"289","author":"T Shimada","year":"2005","unstructured":"Shimada T, Yamazaki Y, Takahashi M et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005; 289:F1088\u20131095.","journal-title":"Am J Physiol Renal Physiol"},{"key":"10_CR52","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/01.mnh.0000172717.49476.80","volume":"14","author":"M Fukagawa","year":"2005","unstructured":"Fukagawa M, Nii-Kono T, Kazama JJ. Role of fibroblast growth factor 23 in health and in chronic kidney disease. Curr Opin Nephrol Hypertens 2005; 14:325\u2013329.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10_CR53","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1681\/ASN.2005010052","volume":"16","author":"O Gutierrez","year":"2005","unstructured":"Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16:2205\u20132215.","journal-title":"J Am Soc Nephrol"},{"key":"10_CR54","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1744-9987.2005.00291.x","volume":"9","author":"JJ Kazama","year":"2005","unstructured":"Kazama JJ, Gejyo F, Shigematsu T et al. Role of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism. Ther Apher Dial 2005; 9:328\u2013330.","journal-title":"Ther Apher Dial"},{"key":"10_CR55","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1172\/JCI108855","volume":"60","author":"MK Drezner","year":"1977","unstructured":"Drezner MK, Feinglos MN. Osteomalacia due to 1alpha,25-dihydroxycholecalciferol deficiency. Association with a giant cell tumor of bone. J Clin Invest 1977; 60:1046\u20131053.","journal-title":"J Clin Invest"},{"key":"10_CR56","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1056\/NEJM199406093302310","volume":"330","author":"MJ Econs","year":"1994","unstructured":"Econs MJ, Drezner MK. Tumor-induced osteomalacia\u2014unveiling a new hormone. N Engl J Med 1994; 330:1679\u20131681.","journal-title":"N Engl J Med"},{"key":"10_CR57","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1128\/MCB.02249-06","volume":"27","author":"R Goetz","year":"2007","unstructured":"Goetz R, Beenken A, Ibrahimi OA et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007; 27:3417\u20133428.","journal-title":"Mol Cell Biol"},{"key":"10_CR58","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd2792","volume":"8","author":"A Beenken","year":"2009","unstructured":"Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009; 8:235\u2013253.","journal-title":"Nat Rev Drug Discov"},{"key":"10_CR59","doi-asserted-by":"publisher","first-page":"6120","DOI":"10.1074\/jbc.C500457200","volume":"281","author":"H Kurosu","year":"2006","unstructured":"Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281:6120\u20136123.","journal-title":"J Biol Chem"},{"key":"10_CR60","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/nature05315","volume":"444","author":"I Urakawa","year":"2006","unstructured":"Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444:770\u2013774.","journal-title":"Nature"},{"key":"10_CR61","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/36285","volume":"390","author":"M Kuroo","year":"1997","unstructured":"Kuroo M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390:45\u201351.","journal-title":"Nature"},{"key":"10_CR62","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1210\/en.2005-0670","volume":"146","author":"X Yu","year":"2005","unstructured":"Yu X, Ibrahimi OA, Goetz R et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 2005; 146:4647\u20134656.","journal-title":"Endocrinology"},{"key":"10_CR63","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.bone.2004.06.014","volume":"35","author":"M Mirams","year":"2004","unstructured":"Mirams M, Robinson BG, Mason RS et al. Bone as a source of FGF23: regulation by phosphate? Bone 2004; 35:1192\u20131199.","journal-title":"Bone"},{"key":"10_CR64","doi-asserted-by":"publisher","first-page":"E38","DOI":"10.1152\/ajpendo.00008.2006","volume":"291","author":"S Liu","year":"2006","unstructured":"Liu S, Zhou J, Tang W et al. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006; 291:E38\u201349.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10_CR65","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1359\/jbmr.080417","volume":"23","author":"Y Yamazaki","year":"2008","unstructured":"Yamazaki Y, Tamada T, Kasai N et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 2008; 23:1509\u20131518.","journal-title":"J Bone Miner Res"},{"key":"10_CR66","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1681\/ASN.2007121301","volume":"19","author":"S Liu","year":"2008","unstructured":"Liu S, Vierthaler L, Tang W et al. FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 2008; 19:2342\u20132350.","journal-title":"J Am Soc Nephrol"},{"key":"10_CR67","doi-asserted-by":"publisher","first-page":"F282","DOI":"10.1152\/ajprenal.90742.2008","volume":"297","author":"J Gattineni","year":"2009","unstructured":"Gattineni J, Bates C, Twombley K et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 2009; 297:F282\u2013291.","journal-title":"Am J Physiol Renal Physiol"},{"key":"10_CR68","doi-asserted-by":"publisher","first-page":"F769","DOI":"10.1152\/ajprenal.00248.2006","volume":"292","author":"H Segawa","year":"2007","unstructured":"Segawa H, Yamanaka S, Ohno Y et al. Correlation between hyperphosphatemia and type II Na-Pi cotransporter activity in klotho mice. Am J Physiol Renal Physiol 2007; 292:F769\u2013779.","journal-title":"Am J Physiol Renal Physiol"},{"key":"10_CR69","first-page":"318","volume":"7","author":"S Ichikawa","year":"2007","unstructured":"Ichikawa S, Imel EA, Kreiter ML et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Musculoskelet Neuronal Interact 2007; 7:318\u2013319.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10_CR70","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1523-1755.2000.00807.x","volume":"57","author":"MK Drezner","year":"2000","unstructured":"Drezner MK. PHEX gene and hypophosphatemia. Kidney Int 2000; 57:9\u201318.","journal-title":"Kidney Int"},{"key":"10_CR71","doi-asserted-by":"crossref","unstructured":"The HYP Consortium. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 1995; 11:130\u2013136.","DOI":"10.1038\/ng1095-130"},{"key":"10_CR72","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1172\/JCI119276","volume":"99","author":"L Beck","year":"1997","unstructured":"Beck L, Soumounou Y, Martel J et al. Pex\/PEX tissue distribution and evidence for a deletion in the 3\u2032 region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest 1997; 99:1200\u20131209.","journal-title":"J Clin Invest"},{"key":"10_CR73","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/jbmr.5650040407","volume":"4","author":"RA Meyer Jr","year":"1989","unstructured":"Meyer RA Jr, Meyer MH, Gray RW. Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. J Bone Miner Res 1989; 4:493\u2013500.","journal-title":"J Bone Miner Res"},{"key":"10_CR74","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/jbmr.5650040411","volume":"4","author":"RA Meyer Jr","year":"1989","unstructured":"Meyer RA Jr, Tenenhouse HS, Meyer MH et al. The renal phosphate transport defect in normal mice parabiosed to X-linked hypophosphatemic mice persists after parathyroidectomy. J Bone Miner Res 1989; 4:523\u2013532.","journal-title":"J Bone Miner Res"},{"key":"10_CR75","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI115735","volume":"89","author":"T Nesbitt","year":"1992","unstructured":"Nesbitt T, Coffman TM, Griffiths R et al. Crosstransplantation of kidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect. J Clin Invest 1992; 89:1453\u20131459.","journal-title":"J Clin Invest"},{"key":"10_CR76","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/00041552-199701000-00004","volume":"6","author":"M Grieff","year":"1997","unstructured":"Grieff M. New insights into X-linked hypophosphatemia. Curr Opin Nephrol Hypertens 1997; 6:15\u201319.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0303-7207(97)00111-1","volume":"132","author":"AE Nelson","year":"1997","unstructured":"Nelson AE, Mason RS, Robinson BG. The PEX gene: not a simple answer for X-linked hypophosphataemic rickets and oncogenic osteomalacia. Mol Cell Endocrinol 1997; 132:1\u20135.","journal-title":"Mol Cell Endocrinol"},{"key":"10_CR78","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1359\/jbmr.090509","volume":"24","author":"Y Aono","year":"2009","unstructured":"Aono Y, Yamazaki Y, Yasutake J et al. Therapeutic Effects of Anti-FGF23 Antibodies in Hypophosphatemic Rickets\/Osteomalacia. J Bone Miner Res 2009; 24:1879\u20131888.","journal-title":"J Bone Miner Res"},{"key":"10_CR79","unstructured":"Kang Y, Zhang R, Lu Y et al. Crossing Talk between Pi homeostasis and Bone. J Bone Miner Res 2009; 24."},{"key":"10_CR80","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ng1905","volume":"38","author":"JQ Feng","year":"2006","unstructured":"Feng JQ, Ward LM, Liu S et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006; 38:1310\u20131315.","journal-title":"Nat Genet"},{"key":"10_CR81","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/ng1868","volume":"38","author":"B Lorenz-Depiereux","year":"2006","unstructured":"Lorenz-Depiereux B, Bastepe M, Benet-Pages A et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006; 38:1248\u20131250.","journal-title":"Nat Genet"},{"key":"10_CR82","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2169\/internalmedicine.47.0730","volume":"47","author":"S Fukumoto","year":"2008","unstructured":"Fukumoto S. Physiological regulation and disorders of phosphate metabolism\u2014pivotal role of fibroblast growth factor 23. Intern Med 2008; 47:337\u2013343.","journal-title":"Intern Med"},{"key":"10_CR83","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1359\/jbmr.061105","volume":"22","author":"Y Frishberg","year":"2007","unstructured":"Frishberg Y, Ito N, Rinat C et al. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res 2007; 22:235\u2013242.","journal-title":"J Bone Miner Res"},{"key":"10_CR84","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1210\/en.2008-0877","volume":"150","author":"S Ichikawa","year":"2009","unstructured":"Ichikawa S, Sorenson AH, Austin AM et al. Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression. Endocrinology 2009; 150:254","journal-title":"Endocrinology"}],"container-title":["Advances in Experimental Medicine and Biology","Endocrine FGFs and Klothos"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4614-0887-1_10.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T08:48:40Z","timestamp":1619858920000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4614-0887-1_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"ISBN":["9781461408864","9781461408871"],"references-count":84,"URL":"https:\/\/doi.org\/10.1007\/978-1-4614-0887-1_10","relation":{},"ISSN":["0065-2598"],"issn-type":[{"type":"print","value":"0065-2598"}],"subject":[],"published":{"date-parts":[[2012]]}}}